|Bid||0.00 x 1100|
|Ask||0.00 x 900|
|Day's Range||11.03 - 11.81|
|52 Week Range||8.45 - 49.20|
|Beta (3Y Monthly)||1.61|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.63|
Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for review its supplemental New Drug Application for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed therapy .
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on September 4, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 48,750 shares of Puma common stock to five new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
LOS ANGELES-- -- First regulatory approval of NERLYNX in Latin America. NERLYNX is the first approved therapy to reduce the risk of invasive disease recurrence in HER2-positive breast cancer patients following trastuzumab-based adjuvant treatment. Up to 25% of HER2-positive early stage breast cancer patients treated with a trastuzumab-based regimen experience a recurrence. Puma Biotechnology, Inc. ...
Puma Biotechnology Inc (NASDAQ: PBYI ) shares advanced in premarket trading Wednesday on the back of an announcement concerning its breast cancer drug Nerlynx before falling after the market open. What ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results ...
Puma Biotechnology Inc. shares rallied in the extended session Tuesday after the drug developer said the Food and Drug Administration granted its cancer treatment a special designation. Puma shares rose 7.4% after hours, following a 3% decline to close the regular session at $10.43. The company said the FDA granted an "orphan drug" designation for its drug Nerlynx for the treatment of breast cancer patients with brain metastases. An orphan drug designation gives a drug maker incentives such as grant funding toward clinical trial costs and a possible seven years of market exclusivity to treat conditions that affect 200,000 people or less in the U.S.
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:35 a.m. EDT on Tuesday, September 10, at the H.C. Wainwright 21st Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City. A live webcast of the presentation will be available on the Company’s website at www.pumabiotechnology.com.
Puma Biotechnology, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to NERLYNX® for the treatment of breast cancer patients with brain metastases.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2019. Unless otherwise stated, all comparisons are for the second quarter 2019 compared to the second quarter of 2018.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.
Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.